Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 7:00 AM CET
Settings

Settings

Goto Application

1. WO1996002669 - CONJUGATES OF METAL COMPLEXES AND OLIGONUCLEOTIDES, WHICH SPECIFICALLY BOND TO SPECIFIC TARGET STRUCTURES, AGENTS CONTAINING THESE CONJUGATES, THEIR USE IN NMR DIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION

Publication Number WO/1996/002669
Publication Date 01.02.1996
International Application No. PCT/EP1995/002686
International Filing Date 12.07.1995
Chapter 2 Demand Filed 22.12.1995
IPC
A61K 49/08 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
49Preparations for testing in vivo
06Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations
08characterised by the carrier
C07H 21/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
CPC
A61K 49/085
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
49Preparations for testing in vivo
06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
08characterised by the carrier
085conjugated systems
A61K 49/126
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
49Preparations for testing in vivo
06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
08characterised by the carrier
10Organic compounds
12Macromolecular compounds
126Linear polymers, e.g. dextran, inulin, PEG
C07H 21/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Applicants
  • SCHERING AKTIENGESELLSCHAFT [DE]/[DE] (AllExceptUS)
  • NEXSTAR PHARMACEUTICALS, INC. [US]/[US] (AllExceptUS)
  • PLATZEK, Johannes [DE]/[DE] (UsOnly)
  • NIEDBALLA, Ulrich [DE]/[DE] (UsOnly)
  • RADÜCHEL, Bernd [DE]/[DE] (UsOnly)
  • MÜHLER, Andreas [DE]/[US] (UsOnly)
  • SPECK, Ulrich [DE]/[DE] (UsOnly)
  • BERNDORFF, Dietmar [DE]/[DE] (UsOnly)
  • GOLD, Larry [US]/[US] (UsOnly)
  • PIEKEN, Wolfgang [DE]/[US] (UsOnly)
Inventors
  • PLATZEK, Johannes
  • NIEDBALLA, Ulrich
  • RADÜCHEL, Bernd
  • MÜHLER, Andreas
  • SPECK, Ulrich
  • BERNDORFF, Dietmar
  • GOLD, Larry
  • PIEKEN, Wolfgang
Priority Data
P 44 24 923.314.07.1994DE
P 44 45 076.105.12.1994DE
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CONJUGATES OF METAL COMPLEXES AND OLIGONUCLEOTIDES, WHICH SPECIFICALLY BOND TO SPECIFIC TARGET STRUCTURES, AGENTS CONTAINING THESE CONJUGATES, THEIR USE IN NMR DIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION
(FR) CONJUGUES DE COMPLEXES METALLIQUES ET D'OLIGONUCLEOTIDES, SE FIXANT DE FAÇON SPECIFIQUE A DES STRUCTURES CIBLES SPECIFIQUES, AGENTS CONTENANT CES CONJUGUES, LEUR UTILISATION DANS LE DIAGNOSTIC PAR RMN AINSI QUE LEUR PROCEDE DE PRODUCTION
Abstract
(EN)
This invention relates to chemically modified oligonucleotide conjugates that contain a complexing agent or complex that is bound by a connecting component to the oligonucleotides. In this case, the oligonucleotides are modified in a way that prevents or at least significantly inhibits the degradation by naturally occurring nucleases. The oligonucleotide radical can bond specifically and with high bonding affinity to target structures and can thus produce a specific therapeutic or diagnostic effect by the bound complexing agent or complex.
(FR)
L'invention concerne des conjugués d'oligonucléotides modifiés chimiquement qui contiennent un agent complexant ou un complexe fixé par un composant de liaison aux oligonucléotides. Dans ce cas, les oligonucléotides sont modifiés selon une méthode empêchant ou au moins inhibant de façon importante la dégradation par des nucléases d'origine naturelle. Le radical de l'oligonucléotide peut se fixer de façon spécifique et avec une grande affinité de liaison à des structures cibles et peut donc produire un effet diagnostique ou thérapeutique spécifique au moyen de l'agent complexant ou du complexe fixé.
Also published as
Latest bibliographic data on file with the International Bureau